Last reviewed · How we verify
Jina Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
2 Phase 3
1 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Conventional paclitaxel or Taxol | Conventional paclitaxel or Taxol | phase 3 | Taxane; microtubule stabilizer | β-tubulin | Oncology | |
| Paclitaxel Lipid Suspension | Paclitaxel Lipid Suspension | phase 3 | Taxane | Microtubules | Oncology |
Therapeutic area mix
- Oncology · 2
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Akeso · 2 shared drug classes
- Sanofi · 2 shared drug classes
- Barts & The London NHS Trust · 1 shared drug class
- Athenex, Inc. · 1 shared drug class
- Bio-Thera Solutions · 1 shared drug class
- BeyondSpring Pharmaceuticals Inc. · 1 shared drug class
- Aravive, Inc. · 1 shared drug class
- Air Force Military Medical University, China · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Jina Pharmaceuticals Inc.:
- Jina Pharmaceuticals Inc. pipeline updates — RSS
- Jina Pharmaceuticals Inc. pipeline updates — Atom
- Jina Pharmaceuticals Inc. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Jina Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/jina-pharmaceuticals-inc. Accessed 2026-05-16.